[go: up one dir, main page]

ATE539170T1 - Abschätzung und verringerung des risikos von graft-versus-host-reaktion - Google Patents

Abschätzung und verringerung des risikos von graft-versus-host-reaktion

Info

Publication number
ATE539170T1
ATE539170T1 AT07719640T AT07719640T ATE539170T1 AT E539170 T1 ATE539170 T1 AT E539170T1 AT 07719640 T AT07719640 T AT 07719640T AT 07719640 T AT07719640 T AT 07719640T AT E539170 T1 ATE539170 T1 AT E539170T1
Authority
AT
Austria
Prior art keywords
assessing
versus host
graft versus
risk
reducing
Prior art date
Application number
AT07719640T
Other languages
English (en)
Inventor
Claude Perreault
Chantal Baron
Roland Somogyi
Larry Greller
Original Assignee
Univ Montreal
Biosystemix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal, Biosystemix Ltd filed Critical Univ Montreal
Application granted granted Critical
Publication of ATE539170T1 publication Critical patent/ATE539170T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • G01N2800/245Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07719640T 2006-04-27 2007-04-27 Abschätzung und verringerung des risikos von graft-versus-host-reaktion ATE539170T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74576106P 2006-04-27 2006-04-27
PCT/CA2007/000714 WO2007124578A1 (en) 2006-04-27 2007-04-27 Assessment and reduction of risk of graft-versus-host disease

Publications (1)

Publication Number Publication Date
ATE539170T1 true ATE539170T1 (de) 2012-01-15

Family

ID=38655008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07719640T ATE539170T1 (de) 2006-04-27 2007-04-27 Abschätzung und verringerung des risikos von graft-versus-host-reaktion

Country Status (6)

Country Link
US (4) US7763425B2 (de)
EP (1) EP2021534B1 (de)
JP (1) JP5171812B2 (de)
AT (1) ATE539170T1 (de)
CA (1) CA2650507A1 (de)
WO (1) WO2007124578A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957704A1 (en) 2004-01-21 2005-08-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
EP2604703B1 (de) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Verfahren zur Bewertung der Haltbarkeit eines Pfropfs im Körper eines Empfängers fester Organtransplantate
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
WO2009075811A1 (en) * 2007-12-07 2009-06-18 Tufts Medical Center, Inc. Compositions and methods for immortalizing cells and screening for anti-cancer agents
CN101960022A (zh) * 2008-01-22 2011-01-26 维里德克斯有限责任公司 Ⅱ期和ⅲ期结肠癌的分子分期和预后
US20110201519A1 (en) * 2008-08-18 2011-08-18 Sarwal Minnie M Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject
CN106755415A (zh) 2009-01-15 2017-05-31 小利兰·斯坦福大学托管委员会 用于诊断和预测移植物排斥的生物标志物板
WO2010096160A1 (en) * 2009-02-17 2010-08-26 The Board Of Trustees Of The Leland Stanford Junior University Compartment-specific non-hla targets for diagnosis and prediction of graft outcome
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
EP3185013B1 (de) 2009-12-02 2019-10-09 The Board of Trustees of the Leland Stanford Junior University Biomarker zur bestimmung eines allotransplantattoleranten phänotyps
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
WO2011119980A1 (en) 2010-03-25 2011-09-29 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
US20120277999A1 (en) * 2010-10-29 2012-11-01 Pbd Biodiagnostics, Llc Methods, kits and arrays for screening for, predicting and identifying donors for hematopoietic cell transplantation, and predicting risk of hematopoietic cell transplant (hct) to induce graft vs. host disease (gvhd)
JP6029470B2 (ja) * 2010-12-06 2016-11-24 大日本住友製薬株式会社 ヒトモノクローナル抗体
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
GB201021149D0 (en) * 2010-12-14 2011-01-26 Georg August Uni Gottingen Stiftung Offentlichen Rechts Use of a skin explant assay for mRNA expression analysis for the identification of new genes and drug targets associated with graft versus host disease
US8962261B2 (en) 2011-04-06 2015-02-24 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for IGA nephropathy
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
ES2632444T5 (es) 2011-09-30 2022-03-02 Bluebird Bio Inc Compuestos que mejoran la transducción viral
JP5904801B2 (ja) * 2012-01-17 2016-04-20 シスメックス株式会社 制御性t細胞への分化誘導能の予測方法及びその方法に用いられるバイオマーカー、並びにそれらの利用
JP6106277B2 (ja) * 2012-10-05 2017-03-29 日立化成株式会社 尿中エキソソームmRNAおよびそれを用いて糖尿病性腎症を検出する方法
US9662649B2 (en) 2013-05-06 2017-05-30 Hitachi Chemical Company America, Ltd. Devices and methods for capturing target molecules
US20160169890A1 (en) * 2013-05-20 2016-06-16 The Trustees Of Columbia University In The City Of New York Tracking donor-reactive tcr as a biomarker in transplantation
EP3140762B1 (de) 2014-05-07 2020-01-08 Pirche Ag Methoden und systeme zur vorhersage der alloreaktivität bei transplantationen
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
EP3218521B1 (de) 2014-11-12 2019-12-25 Hitachi Chemical Co., Ltd. Verfahren zur diagnose von organverletzung
US9563744B1 (en) * 2014-12-03 2017-02-07 Biodesix, Inc. Method of predicting development and severity of graft-versus-host disease
CN104878099B (zh) * 2015-05-15 2018-02-16 西北农林科技大学 山羊atbf1基因单核苷酸多态性的检测方法及其应用
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
CN108713059A (zh) 2016-02-12 2018-10-26 蓝鸟生物公司 Vcn增强子组合物和其使用方法
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
WO2019014667A1 (en) * 2017-07-14 2019-01-17 The Regents Of The University Of California NEW METHODS FOR PREDICTING THE RISK OF GRAFT REJECTION
WO2020158832A1 (ja) * 2019-01-30 2020-08-06 Icaria株式会社 生体分子回収デバイス並びに方法、生体分子分析デバイス並びに方法
SG11202112347RA (en) * 2019-05-23 2021-12-30 Spacecraft Seven Llc Gene therapy vectors for infantile malignant osteopetrosis
TW202409285A (zh) * 2022-04-22 2024-03-01 美商航天七號有限責任公司 使用aav載體之b細胞淋巴瘤2相關抗凋亡3(bag3)基因療法
WO2024151826A1 (en) * 2023-01-12 2024-07-18 Jasper Therapeutics, Inc. Methods for the prevention and treatment of gvhd

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200303132B (en) 2000-10-20 2004-09-23 Expression Diagnostics Inc Leukocyte expression profiling.
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
ATE546547T1 (de) * 2002-08-22 2012-03-15 Novartis Pharma Gmbh Diagnose der chronischen abstossung
JP4316617B2 (ja) * 2003-12-03 2009-08-19 ノバルティス アクチエンゲゼルシャフト 移植片拒絶反応のバイオマーカー
WO2005074540A2 (en) * 2004-01-30 2005-08-18 University Of Pennsylvania Novel predictors of transplant rejection determined by peripheral blood gene-expression profiling

Also Published As

Publication number Publication date
EP2021534A4 (de) 2009-11-11
US20130324427A1 (en) 2013-12-05
EP2021534A1 (de) 2009-02-11
CA2650507A1 (en) 2007-11-08
US9102981B2 (en) 2015-08-11
US7763425B2 (en) 2010-07-27
US20100248254A1 (en) 2010-09-30
EP2021534B1 (de) 2011-12-28
WO2007124578A1 (en) 2007-11-08
US20150337374A1 (en) 2015-11-26
US20070264272A1 (en) 2007-11-15
JP2009538599A (ja) 2009-11-12
JP5171812B2 (ja) 2013-03-27

Similar Documents

Publication Publication Date Title
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
ATE452149T1 (de) Modifizierte polyolefinwachse
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
WO2007047408A3 (en) Promac signature application
ATE517992T1 (de) Funktionelle und hyperfunktionelle sirna
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
MY144672A (en) Inhibitors of cytosolic phospholipase a2
DK1737974T3 (da) Fremgangsmåder til identifikation af proteiner med stivelsesphosphorylerende enzymatisk aktivitet
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
EA200702193A1 (ru) Гликозилирование белков
DE602007002568D1 (de) Chloramphenicolresistenz-selektion bei bacillus licheniformis
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
DE602007000894D1 (de) Verstärkte Reaktivierung wärmebeständiger, reversibel inaktivierter Enzyme
WO2005065365A3 (en) Systems and methods for aesthetic improvement
BRPI0604502A (pt) controles de ensino de metilação de gene
ITMO20030081A0 (it) Bioreattore,particolarmente per organi bioartificiali.
ATE447628T1 (de) Einzelsequenzhybridisierungssonden
ATE556446T1 (de) Batterieanoden
WO2005074540A3 (en) Novel predictors of transplant rejection determined by peripheral blood gene-expression profiling
EA200970074A1 (ru) Химический способ создания давления